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Abstract
Introduction Neglected tropical diseases (NTDs) affect
more than one billion people, mainly living in developing
countries. For most of these NTDs, treatment is subopti-
mal. To optimize treatment regimens, clinical pharma-
cokinetic studies are required where they have not been
previously conducted to enable the use of pharmacometric
modeling and simulation techniques in their application,
which can provide substantial advantages.
Objectives Our aim was to provide a systematic overview
and summary of all clinical pharmacokinetic studies in
NTDs and to assess the use of pharmacometrics in these
studies, as well as to identify which of the NTDs or which
treatments have not been sufficiently studied.
Methods PubMed was systematically searched for all
clinical trials and case reports until the end of 2015 that
described the pharmacokinetics of a drug in the context of
treating any of the NTDs in patients or healthy volunteers.
Results Eighty-two pharmacokinetic studies were identi-
fied. Most studies included small patient numbers (only
five studies included[50 subjects) and only nine (11 %)
studies included pediatric patients. A large part of the
studies was not very recent; 56 % of studies were published
before 2000. Most studies applied non-compartmental
analysis methods for pharmacokinetic analysis (62 %).
Twelve studies used population-based compartmental
analysis (15 %) and eight (10 %) additionally performed
simulations or extrapolation. For ten out of the 17 NTDs,
none or only very few pharmacokinetic studies could be
identified.
Conclusions For most NTDs, adequate pharmacokinetic
studies are lacking and population-based modeling and
simulation techniques have not generally been applied.
Pharmacokinetic clinical trials that enable population
pharmacokinetic modeling are needed to make better use of
the available data. Simulation-based studies should be
employed to enable the design of improved dosing regi-
mens and more optimally use the limited resources to
effectively provide therapy in this neglected area.
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Neglected tropical diseases affect a major part of the
global population, but treatments have generally not
been optimized.
We provide a comprehensive systematic overview of
performed pharmacokinetic studies in all 17
neglected tropical diseases, advantages and
drawbacks of different methodologies, and gaps in
pharmacokinetic research through which neglected
tropical diseases therapeutics can be further
improved.
For most neglected tropical diseases, adequate
pharmacokinetic studies were found lacking or
completely absent, pediatric patients have largely
been ignored, and population-based modeling and
simulation techniques have not generally been
applied.
To more optimally use the limited available
resources in this neglected area, more emphasis
should be given to simulation-based
pharmacokinetic studies enabling the design of
improved dosing regimens.
1 Introduction
Neglected tropical diseases (NTDs) represent a wide range
of infectious afflictions, which are prevalent mostly in
tropical and subtropical countries and have one common
characteristic: they all affect people living in deep poverty.
All NTDs are heavily debilitating, causing life-long dis-
ability, which can be directly fatal if left untreated. At the
moment, over 1.4 billion people are affected by at least one
NTD, and they are the cause of death for over 500,000
people annually [1, 2]. There are currently 17 NTDs as
defined by the World Health Organization (WHO), which
include protozoal, bacterial, helminth, and viral infections
[1]. An overview of their transmission, geography, and
burden of disease is provided in Table 1. Collectively, the
NTDs belong to the most devastating of communicable
diseases, not only in terms of global health burden (26.1
million disability-adjusted life-years) [3, 4], but also in
terms of impact on development and overall economic
productivity in low- and middle-income countries [3, 5].
The currently available treatments for NTDs are an
outdated arsenal generally considered to be insufficient for
NTD control and elimination [5]. Many of the currently
available drugs were developed over 50 years ago and
many of them exhibit high toxicity [5]. For example, the
only available drug to treat late-stage human African try-
panosomiasis (or sleeping sickness) caused by T. b.
rhodesiense is melarsoprol, an arsenic compound, devel-
oped in the 1940s, which is itself lethal to 5 % of treated
patients owing to post-treatment reactive encephalopathy
[6]. In many regions, pentavalent antimony-containing
compounds are still the treatment of choice for visceral
leishmaniasis (VL) and cutaneous leishmaniasis, which
have been in use since the 1930s. Therapeutic failure is
generally thought to result from sub-therapeutic dosing and
shortened treatment durations [7]. As a consequence,
clinical antimonial drug resistance in Leishmania has
yielded the drug useless in various geographical regions. At
the same time, the upper limit of dosing of antimonials is
limited by severe toxicities, such as pancreatitis and car-
diotoxicity [7, 8]. Examples like these emphasize the role
of dose optimization and pharmacokinetic (PK) studies for
treatments against NTDs, where there is often only a small
therapeutic window between treatment failure, engendering
drug resistance, and drug toxicity.
Despite the urgent need for new, safer, and more effi-
cacious treatments for NTDs, there is insufficient interest
from the pharmaceutical industry to invest in drug devel-
opment for these diseases because of the limited financial
incentive. This paradigm has led to a fatal imbalance in
drug development: although NTDs account for 12 % of the
global disease burden, only 1 % of all approved drugs
during the past decade was developed for these diseases.
None of these approved drugs were a new chemical entity,
and just 0.5 % of all clinical trials in the past decade were
dedicated to NTDs [9].
Owing to the lack of innovation as a result of the
absence of financial incentives and the continued use of
drugs developed many decades ago, dose-optimization
studies or studies in specific patient populations particu-
larly affected by NTDs (e.g., pediatric or HIV co-infected
patients) have rarely been reported. While a comprehensive
and quantitative overview is currently lacking, only a few
clinical trials on NTDs appear to have included studies on
the pharmacokinetics of the therapeutic compounds that
were under clinical investigation. Rational drug therapy is
based on the assumption of a causal relationship between
exposure and response. Therefore, characterizing the
pharmacokinetics of a drug is of utmost importance.
Conventionally, non-compartmental analysis (NCA)
methods were used for PK analysis, but these are less
powerful and informative for typical NTD PK studies,
which are sparse and heterogeneous in nature. NCA has a
low power to identify true covariate effects and does not
allow for simulations of alternative dosing regimens.
Population-based modeling and simulation techniques are
therefore more appropriate to describe and predict the
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Table 1 Summary of neglected tropical diseases including endemic areas, causative agents, method of transmission, and estimated global
burden expressed in deaths per year and DALYsa





Chagas disease Latin America Trypanosoma cruzi Triatomine bug 10,300 0.55
Human African
trypanosomiasis
Africa Trypanosoma brucei gambiense,
T. brucei rhodesiense
Tsetse fly 9100 0.56





Cutaneous: L. major, L. tropica, L. braziliensis, L.





Buruli ulcer Africa, South America,
Western Pacific regions
Mycobacterium ulcerans Unknown n.d. n.d.




Mycobacterium leprae Unknown n.d. 0.006
Trachoma Africa, Middle East,
Mexico, Asia, South
America, Australia








Global distribution Treponema pallidum, T. carateum Skin contact n.d. n.d.
Helminthes
Cysticercosis/taeniasis Worldwide, mainly
Africa, Asia, and Latin
America



















Clonorchis spp., Opisthorchis spp., Fasciola spp.,
and Paragonimus spp., Echinostoma spp.,





Lymphatic filariasis Africa, Asia, Central and
South America
Wuchereria bancrofti, Brugia malayi, B. timori Mosquitos - 2.78
Onchocerciasis Africa, Latin America,
Yemen




Schistosoma haematobium, S. guineensis, S.







Global distribution Ascaris lumbricoides, Trichuris trichiura, Necator
americanus, Ancylostoma duodenale
Human feces 2700 5.19
Viral infections
Dengue Asian and Latin
American countries





Rabies virus (genus: Lyssavirus) Animals, mostly
domestic dogs
26,400 1.46
DALYs disability-adjusted life-years, n.d. not determined
a Numbers are based on the Global Burden of Disease Study 2010 [4]
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relationship between exposure (pharmacokinetics),
response (pharmacodynamics), individual patient charac-
teristics, and other covariates of interest (e.g., body weight,
sex, and concomitant medication). These pharmacometric
methods have become standard in drug development
worldwide, and have been recommended by the US Food
and Drug Administration and the European Medicines
Agency for PK–pharmacodynamic (PD) data analysis and
clinical trial design, particularly in pediatric and small-
sized patient populations [10–12]. Nevertheless, these
methodologies appear to be systematically underused to
address NTDs, likely because their advent occurred much
later than the time when many of these drugs were
developed.
To better understand to what extent clinical PK studies
have contributed to optimization of treatment regimens for
NTDs, we performed a systematic review of published
clinical PK studies on NTD therapeutics. We hypothesize
that for many of the NTD therapeutics, proper PK studies
and thus a rationale for their dosing are plainly missing,
and that only a few of these studies use modeling and
simulation tools. By providing a comprehensive overview
of performed PK studies, we illustrate the advantages and
drawbacks of different PK methodologies and we identity
the gaps in PK research for particular NTDs to indicate the
areas where NTD therapeutics can be further improved.
2 Methods
2.1 Study Identification
We performed a systematic literature review following
applicable criteria of the most current PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Anal-
yses) guidelines [13], the PRISMA Checklist is in
Appendix 1. The MEDLINE database was systematically
searched through PubMed for all human clinical PK studies
until September 2015 that described the clinical pharma-
cokinetics of a drug in the treatment of any of the NTDs.
For instance, the search term used for studies for Chagas
disease was: ((Chagas disease[Title/Abstract] OR Ameri-
can trypanosomiasis[Title/Abstract])) AND (pharmacoki-
netics[Title/Abstract] OR pharmacokinetic[Title/
Abstract]). Reviews were excluded from the search, as well
as preclinical research and research concerning animals
other than humans. The search was limited to publications
in English. A full list of all the search terms used is shown
in Supplemental Table 1.
Secondary literature was identified using the bibliogra-
phies of the primary identified literature and by specifically
querying PubMed using the drug name in combination with
the disease. Because we were particularly interested in the
application of population PK approaches in NTDs, the
abstracts of the Population Approach Group Europe con-
ference [14] were also searched using the same search
terms. No specific protocol was developed for this sys-
tematic review.
2.2 Study Selection
Records were initially screened to identify relevant publi-
cations based on title and abstract. If the abstract lacked
sufficient detail, the full publication was assessed. The aim
of this study was the identification of clinical PK studies in
the context of the treatment of NTDs, and therefore studies
were excluded if the study’s subjects were not healthy
subjects (phase I studies) or patients diagnosed with one of
the NTDs; or if the drug of interest was symptomatic
treatment (e.g., suppression of fever) or for treatment of
concomitant diseases instead of the NTD itself (primary
criteria). Articles with only pharmacodynamic results or
only reporting a bioanalytical method were also excluded.
2.3 Assessment of Pharmacokinetic Data Analysis
Methods
The methods used to analyze the PK data were extracted
from the identified records and qualitatively categorized as
follows, in order of level of complexity: (I) comparison of
average trough/steady-state concentrations, (II) NCA, (III)
individual-based compartmental analysis, (IV) population-
based compartmental analysis, and (V) the use of simula-
tions and/or extrapolations. In category I, studies were
included that basically compared a drug concentration at a
single time point between different formulations or dif-
ferent patient groups. In category II, we included studies
that described concentration-time profiles or PK parame-
ters by using NCA techniques [15]. Analyses in category
III used non-linear equations to describe individual con-
centration-time curves, by using theoretical compartments
and inter-compartmental transfer rates, deriving individual
PK parameters that can be averaged. In population-based
analysis (category IV), similar techniques are being used,
but with simultaneous estimation of both inter- and intra-
individual variability (nonlinear mixed-effects models).
The derived model is descriptive for the entire population
and can subsequently be used for predictions and simula-
tions, and potentially for extrapolation to for instance other
populations (additional category V).
2.4 Extraction and Analysis of Data
Besides the PK data analysis method, other data that were
extracted from the identified study reports were: adminis-
tered compound, measured analytes (parent compound and/
L. Verrest, T. P. C. Dorlo
or metabolites), route of administration, PK sample matrix,
the type and number of subjects, and particularly whether
pediatric patients were included in the study. Additionally,
the main conclusions were extracted from all studies in a
qualitative way, focused on the study recommendations in
regard to dose adjustments or other treatment optimiza-
tions. The risk of bias in these recommendations, for
instance when used analysis methods were insufficient to
support these treatment recommendations, was gauged and
reported if detected. Given the nature of extracted data,




The primary literature search identified 431 unique publi-
cations. After screening, 341 publications were excluded
based on the primary criteria. Combined with additional
articles through secondary sources, 82 publications were
eventually included in this systematic review (Fig. 1). No
full texts were available for six studies; however, the
abstracts of these publications contained all the information
to be extracted and they did not need to be excluded. The
search and inclusion results stratified per NTD are shown
in Supplemental Table 1. A summary of all identified PK
studies together with their main characteristics is shown in
Table 2.
For four out of the 17 (24 %) NTDs, not a single PK
study could be identified, these were yaws, dracunculiasis,
dengue/chikungunya/zika and soil-transmitted helminthi-
ases. For six (41 %) other NTDs, fewer than five PK
studies had been reported. Most studies had included small
patient numbers, only five studies (6.1 %) had included
[50 subjects (Table 2). Pediatric patients were included in
nine (11 %) studies. The majority of these studies were not
very recent; 56 % of studies were published before 2000;
the frequency of studies per year is depicted in Fig. 2.
Concerning the used analysis methods, some studies
employed multiple analysis methods, e.g., both comparison
of steady-state concentrations and NCA (Table 2). When
looking at the most complicated method employed in the
study, most studies used NCA methods for PK analysis
(62 %). Twelve studies (15 %) used population-based
compartmental analysis, of which eight (10 %) additionally
performed simulations or extrapolation. Regarding the aim
of the studies, 38 studies (46 %) focused on describing the
pharmacokinetics of a compound without further interpre-
tations. Only five studies (6 %) evaluated exposure-re-
sponse relationships. Although some of these studies
reported side effects [16–18], none of these attempted to
relate drug exposure to observed toxicity. However, rela-
tively many studies (28 %) evaluated drug–drug and food
interactions. This is owing to the frequent use of combi-
nation therapies for the treatment of NTDs, and the
implementation of overlapping prophylactic mass drug
administrations, e.g., onchocerciasis, lymphatic filariasis,
and schistosomiasis.
3.2 Pharmacokinetic Studies per Neglected Tropical
Disease
Based on the cause of the infection, NTDs can be divided
into four groups: diseases caused by protozoal parasites,
bacteria, helminthes, and viruses (an extensive overview is
provided in Table 1). The protozoal NTDs are all caused
by kinetoplastid parasites: Chagas disease, human African
trypanosomiasis, and leishmaniasis. Bacteria, a large and
diverse group of prokaryotic microorganisms, cause Buruli
ulcer, leprosy (both caused by Mycobacteria), trachoma,
and yaws. Helminthes, commonly known as parasitic
worms, are large multicellular organisms. The helminth
NTDs are cysticercosis/taeniasis, dracunculiasis,
echinococcosis, food-borne trematodiases, lymphatic filar-
iasis, onchocerciasis, schistosomiasis, and the soil-trans-
mitted helminthiases. Viral NTDs include the arboviral
disease dengue (plus chikungunya and zika) and rabies. A
general overview of medicines that are currently in use for
NTDs is listed in Table 3 [1, 19].
We discuss the most salient identified PK studies for
NTD therapies, focusing on studies that played a role in
treatment optimization. A full overview of identified
studies can be found in Table 2.
Records idenﬁed through 




Full-text arcles assessed for 
eligibility (n = 90)
Full-text arcles excluded (n = 15)
- Paents were diagnosed for
diseases other than NTDs (n = 2)
- Analyzed drug was supporve
treatment (n = 11)
- Only analysis method was
described (n = 2)
Studies included in systemac 
review (n = 82)
Records excluded based on 
abstract (n = 341) 
Addional records idenﬁed 
through other sources (n = 7)
Fig. 1 Study flow diagram. NTDs neglected tropical diseases
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3.2.1 Chagas Disease
Around 5.7 million people worldwide are affected by
Chagas disease (also known as American trypanosomiasis),
which is caused by the Trypanosoma cruzi parasite [20].
The acute phase of the disease is asymptomatic in most
patients. During the chronic phase, patients can experience
cardiac, digestive, or neurological symptoms, which com-
plications lead in many patients to fatality in the late
chronic stage mostly decades after the start of infection.
However, Chagas disease can be cured when treatment is
initiated at the acute or early chronic stage. Currently, the
only two drugs with proven efficacy in Chagas disease are
nifurtumox and benznidazole (Table 3). Clinical PK stud-
ies were found for three drugs: allopurinol riboside
[21, 22], nifurtimox [23], and benznidazole [24–26]
(Table 2).
Allopurinol was not further evaluated for the treatment
of Chagas disease after demonstrating suboptimal exposure
[21], which could not be sufficiently increased by probe-
necid co-administration decreasing the drug’s renal excre-
tion [22]. A population PK modeling and simulation
approach was used to estimate the exposure of infants to
nifurtimox via breastmilk of patients [23]. Transfer of
nifurtimox into breastmilk appeared limited and unlikely to
lead to significant exposure in infants, yielding nifurtimox
safe to use for breastfeeding patients. The first PK study on
benznidazole was published in 1980 [24]. Very recently,
population-based analyses were performed in children [25]
and in adults [26]. Model-based simulations in these
studies suggested that the adult daily dose intervals in
chronic Chagas patients could be prolonged, while ben-
znidazole concentrations were kept within the target range,
potentially simplifying the treatment regimen.
3.2.2 Human African Trypanosomiasis
Human African trypanosomiasis, also known as sleeping
sickness, is transmitted by the tsetse fly and caused by T. b.
rhodesiense, resulting in an acute infection, and T. b.
gambiense, leading to a more chronic infection (Table 1).
Without treatment, the infection of the central nervous
system is ultimately fatal [27]. There are currently four
treatments in use for the two different stages of human
African trypanosomiasis (Table 3), all of which exhibit
substantial toxicities: pentamidine, suramin, melarsoprol,
and nifurtimox plus eflornithine. Clinical PK studies were
identified for three of these treatments: pentamidine
[28, 29], melarsoprol [30–33], and eflornithine [34–36].
Additionally, PK studies were found for fexinidazole, a
drug currently still in late-phase clinical development
[37, 38].
Pharmacokinetics played an important role in the opti-
mization of eflornithine therapy. Based on cerebrospinal
fluid (CSF) and plasma PK data from late-stage T. b.
gambiense trypanosomiasis, a new dosing regimen was
proposed for eflornithine, including different infusion
intervals, and increased doses in children, based on body
surface area instead of body weight [34]. Later, it was
shown that the current dosing of oral eflornithine did not
result in adequate therapeutic plasma and CSF concentra-
























Fig. 2 Number of identified
clinical pharmacokinetic
publications on neglected
tropical diseases stratified per
year
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Table 3 Currently used drugs for neglected tropical diseases





Early stage Pentamidine IV, IM
Suramin IV
Late stage Melarsoprol IV
Nifurtimox and eflornithine IV and IV
Leishmaniasis
Meglumine antimoniate IL, IV, IM
Sodium stibogluconate IL, IV, IM
Paromomycin (paromomycin ointment or WR 279396 cream) Topical, IM
Pentamidine IV, IM
Amphotericin B deoxycholate IV










Multibacillary Rifampicin and dapsone Oral and oral














Clonorchiasis and opisthorchiasis Praziquantel Oral
Fascioliasis Triclabendazole Oral







L. Verrest, T. P. C. Dorlo
PK–PD model for the different stereoisomers of eflor-
nithine was developed reanalyzing previous PK data and
showed the importance of stereoselective exposure, which
provided an explanation why oral eflornithine had failed so
far for late-stage human African trypanosomiasis patients
[36].
Melarsoprol pharmacokinetics in plasma and CSF was
assessed using compartmental methods in 19 trypanoso-
miasis patients, after which the typical exposure for safer
alternative dose regimens could be simulated [31]. How-
ever the PK–PD relationships for melarsoprol remain
unclear: melarsoprol PK parameters and CSF/plasma
exposure were not significantly different in refractory
compared with cured patients [32] and arsenic urinary
excretion was not predictive of either toxicity or efficacy of
melarsoprol [30].
Fexinidazole, a nitroimidazole-compound currently in
clinical development for human African trypanosomiasis,
and its active metabolites were studied in healthy volun-
teers. The study showed the need for concomitant food
intake, which increases the bioavailability of this com-
pound substantially, and identified a target dose for the first
in-patient studies [37, 38].
3.2.3 Leishmaniasis
Leishmaniasis is caused by various species of Leishmania
parasites that are transmitted by sandflies, with different
and widespread geographical regions of distribution,
leading to distinctly different clinical presentations. Cuta-
neous leishmaniasis is most prevalent and has the potential
to progress into mucocutaneous leishmaniasis. Visceral
leishmaniasis is the most severe clinical form and is
inevitably fatal if left untreated. Treatment of leishmaniasis
depends on the type of disease, parasite species, and on the
availability of treatment depending on the geographical
location. Local chemotherapeutic treatment with intrale-
sional pentavalent antimonials or paromomycin cream can
be an option for cutaneous leishmaniasis, although some
species or severe/diffuse disease are rather treated sys-
temically with either parenteral antimonials, liposomal
amphotericin B, pentamidine or oral miltefosine, keto-
conazole, and fluconazole [39]. Recommended treatments
for VL are, depending on species and geographical loca-
tion, either parenteral (liposomal) amphotericin B, the
antimonial sodium stibogluconate, paromomycin, oral
miltefosine, or combinations of sodium stibogluconate with
paromomycin (East Africa) or liposomal amphotericin B
plus paromomycin/miltefosine (India). Several clinical PK
studies were conducted in leishmaniasis, and have helped
most notably to optimize dose regimens for miltefosine for
VL [40–43], for antimonials for cutaneous leishmaniasis
[44–46] and for VL [47, 48], to quantify exposure to
paromomycin in VL [49], and to assess systemic penetra-
tion of topical paromomycin formulations [50]. Few stud-
ies have been performed in the context of leishmaniasis on
allopurinol [21, 22] and sitamaquine [51] of which both are
not in clinical use at the moment.
Comparing the two pentavalent antimonial compounds in
use for leishmaniasis, meglumine antimoniate, and sodium
stibogluconate, equivalent systemic exposure was shown for
the active component pentavalent antimony, possibly
Table 3 continued














IL intralesional, IM intramuscular, IV intravenous
a For dracunculiasis, treatment involves removing the adult worm
b Treatment of dengue and chikungunya consists of relieving symptoms
c After exposure by an animal that might have rabies, post-exposure anti-rabies vaccination is recommended to prevent rabies infection
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indicating that they can be used interchangeably [48]. In
cutaneous leishmaniasis, PK studies on parenteral sodium
stibogluconate demonstrated wide variability in drug expo-
sure [44], but also penetration of the active component
antimony in the skin, with no differences between normal
skin and lesions [52]. The first pediatric study of meglumine
antimoniate showed that drug exposure is significantly lower
in children than in adults treatedwith the same linear weight-
adjusted (mg/kg) regimen, possibly indicating that children
are currently undertreated [53]. Only a descriptive analysis
of the pharmacokinetics was performed, which did not sug-
gest or evaluate alternative dose regimens for children.
Systemic penetration of paromomycin and gentamycin
after application of two different topical formulations in
cutaneous leishmaniasis patients was assessed using com-
partmental methods [50]. While gentamycin remained
largely undetectable in plasma, paromomycin accumulated
to 5–9 % of typical trough concentrations achieved after a
standard intramuscular administration of 15 mg/kg paro-
momycin, indicating little concern for systemic drug toxi-
city of the topical formulations.
Most PK studies in leishmaniasis were conducted on the
oral drug miltefosine. In 2008, the first population PK
model for this drug was developed on data from Dutch
military personnel who contracted L. major cutaneous
leishmaniasis in Afghanistan [40]. This analysis showed
that miltefosine is eliminated at a much slower rate than
expected, which has potential implications for emerging
drug resistance and the required contraception period
owing to the teratogenicity of miltefosine. A subsequent
simulation study focused on the translation of the repro-
ductive safety limit in animal studies to Indian female VL
patients. New recommendations for the duration of con-
traceptive cover after miltefosine treatment were provided
based on these findings [41]. In a model-based study,
miltefosine exposure appeared to be lower in children than
in adults treated with the same mg/kg dose, possibly
explaining increased failure rates observed in pediatric VL
patients. A new dosing algorithm based on allometric
scaling was proposed and was evaluated by Monte Carlo
simulations [42]. Recently, a PK–PD model of miltefosine
in Nepalese VL patients indeed identified a PK–PD rela-
tionship between miltefosine exposure and long-term
treatment relapse [43]. The confirmed underexposure in
children, reinforces the need for implementing the earlier
proposed allometric miltefosine dosing regimen for VL
[42, 43].
3.2.4 Buruli Ulcer
Buruli ulcer is an ulcerating infection caused by My-
cobacterium ulcerans, leading to long-term functional
disability, loss of productivity, and stigmatization.
Antimicrobial treatment is particularly effective in small
lesions and at an early stage of infection, it reduces healing
time, recurrence rate, and the need for surgical intervention
[54]. Different combinations of antimicrobials are used,
depending on available resources and the stage of the
disease. The most widely accepted combination is oral
rifampicin with intramuscular streptomycin, the oral com-
bination of rifampicin with clarithromycin is still under
clinical evaluation. Only a single PK study could be
identified for Buruli ulcer, which studied systemic phar-
macokinetics of rifampicin and clarithromycin in patients
using population compartmental methods [55].
In this study, the counteracting interaction effects (both
cytochrome P450 3A4 and P-glycoprotein) of clar-
ithromycin and rifampicin on each other’s pharmacoki-
netics were investigated. Eventually, it was suggested that
a doubled dose of clarithromycin should be evaluated in
future clinical studies to ensure an increased time above the
minimum inhibitory concentration [55].
3.2.5 Leprosy
Leprosy can be divided into paucibacillary and multi-
bacillary disease. If not treated in an early phase, it results
in lifelong neuropathy and disability. A combination of
drugs is needed because of the emergence of drug resis-
tance. In 1995, the WHO supplied free multi-drug therapy
to leprosy patients in all endemic countries, which led to a
dramatic decrease in prevalence. For paucibacillary treat-
ment, the recommended all oral treatment combination is
rifampicin plus dapsone, for multibacillary treatment; this
combination should be extended with clofazimine
(Table 3). Various PK studies have been conducted on
dapsone [56–59], clofazimine [60], and specific drug–drug
interaction studies focusing on the interactions between
dapsone, clofazimine, and rifampicine using various for-
mulations [61–64]. A few studies focused on thalidomide
pharmacokinetics [65, 66], which is currently largely
considered obsolete because of its teratogenicity. PK
studies for leprosy were mainly performed in the 1980/90s
and generally using NCA methods (Table 2).
A study on dapsone and its main active metabolite
monoacetyldapsone in leprosy patients concluded that the
standard 100-mg/day dose was sufficient to maintain
therapeutic plasma concentrations in relation to in vitro
susceptibility values [58]. Nevertheless, dose adjustments
might be needed for obese patients treated with this regi-
men [59]. Various drug–drug interaction studies did not
reveal clinical significant interactions, although little is
known about the required minimal effective exposure in
leprosy [61–64].
Pharmacokinetics of clofazimine has been analyzed
using compartmental methods after various fed and fasting
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conditions to determine food effects and the relative
bioavailability [60]. A high-fat meal increased bioavail-
ability significantly and was therefore considered prefer-
able, although exposure–effect relationships for
clofazimine in leprosy have not been properly established.
3.2.6 Trachoma
Trachoma is the leading infectious cause of blindness
worldwide. The infection of the eye by Chlamydia tra-
chomatis can be divided into two clinical stages: initial
active trachoma (inflammation) and cicatricial disease
(eyelid scarring). Active trachoma is mostly seen in young
children and cicatricial disease and eventual blindness are
typically seen in adults. Treatment and prevention of tra-
choma consists of surgery and mass drug administration of
antibiotic treatment. The WHO recommends either single-
dose oral azithromycin or topical tetracycline. Because
trachoma commonly geographically overlaps with other
NTDs such as onchocerciasis and lymphatic filariasis,
regional elimination initiatives for these diseases in terms
of mass drug administrations are often aimed to be com-
bined. Pharmacokinetic studies have therefore focused on
drug–drug interactions between azithromycin and drugs
used in mass drug administration for these other NTDs
(ivermectin and albendazole) [67, 68].
Ivermectin exposure appeared to be increased in healthy
volunteers in combination with azithromycin and the
authors recommended subsequent modeling and simulation
to predict and evaluate an optimal dosing regimen for this
drug combination [67]. A subsequent population PK anal-
ysis of the same data showed the benefit of modeling and
simulation by pinpointing that the mechanism of this
interaction was an increase in bioavailability and demon-
strating that maximum expected ivermectin exposures after
concomitant administration of azithromycin were still
within a well-tolerated range, meaning that combining
these drugs in mass drug administrations should be feasible
[68].
3.2.7 Endemic Treponematoses
Endemic treponematoses are a group of chronic bacterial
infections, related to venereal syphilis, caused by tre-
ponemes that mainly affect the bones and/or skin causing
localized lesions. The spectrum of diseases includes
yaws, endemic syphilis (bejel), and pinta. Yaws is the
most prevalent form of non-venereal treponematosis, and
while rarely fatal, it can lead to chronic disfigurement
and disability. Treatment consists of a single dose of
long-acting penicillin or oral azithromycin. No PK
studies could be identified for drugs used to treat ende-
mic treponematoses.
3.2.8 Cysticercosis/Taeniasis
Cysticercosis and taeniasis are both caused by species of
the Taenia tapeworm. Taeniasis is the intestinal infection
with adult tapeworms. This mild disease is an important
cause for transmission of cysticercosis, an infection with
the larval stage of the pork tapeworm Taenia solium that
can cause life-threatening clinical manifestations. The most
severe form is neurocysticercosis in which the larval cysts
are located in the central nervous system and cause severe
neurological symptoms. The treatment of (neuro-)cys-
ticercosis is not fully established. Besides symptomatic
treatment (antiepileptics), it remains debated whether, and
if so in which cases, antiparasitic and concomitant anti-
inflammatory treatment to reduce inflammation associated
with the dying organism are indicated. The main antipar-
asitic agents used in cysticercosis are albendazole and
praziquantel, while the supportive anti-inflammatory ther-
apy can be corticosteroids or methotrexate. Pharmacoki-
netic studies are available for both albendazole [69–71, 75]
and praziquantel [72–74], and have focused on drug–drug
interactions [71–74].
Albendazole sulfoxide, the main metabolite of alben-
dazole, has been studied in several clinical trials on neu-
rocysticercosis. Despite the absence of an established PK–
PD relationship, these studies suggested based on the area
under the concentration-time curve and steady-state trough
concentrations that albendazole administration could be
changed from the current clinical practice of three times
daily, to twice daily [70, 75]. Conversely, a small
descriptive study in children advised an opposite dose
adjustment, given the increased clearance in children [69].
Drug–drug interaction studies indicated that there were no
interactions with antiepileptic drugs and that dexametha-
sone even decreased the elimination rate of albendazole
[71]. Co-administration of the antiparasitic praziquantel
increased albendazole sulfoxide exposure possibly syner-
gizing the efficacy of both drugs when administered toge-
ther [74].
Drug–drug interaction studies with praziquantel
demonstrated that exposure was decreased in combination
with dexamethasone and anti-epileptic drugs possibly
related to induction of cytochrome P450-mediated hepatic
metabolism [72]. Conversely, co-administration of the
histamine H2-receptor antagonist cimetidine was demon-
strated to prolong exposure of praziquantel, suggesting the
possibility for further improvement of efficacy of this
single-day therapy [73].
3.2.9 Dracunculiasis
Dracunculiasis is also known as guinea-worm disease. The
infection is transmitted by drinking unfiltered water
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containing the larvae of Dracunculus medinensis. Treat-
ment consists of slow extraction of the worm combined
with wound care and pain management. There is no
specific chemotherapy indicated to treat dracunculiasis and
no PK studies were found.
3.2.10 Echinococcosis
There are four species of Echinococcus tapeworms that can
cause infection in humans. Humans are an incidental host;
with transmission through for example, contaminated
environmental water. The two main types of disease are
cystic echinococcosis and alveolar echinococcosis, both
characterized by the slow growth of cyst-like larvae, usu-
ally in the liver. Development of active disease can take
multiple years. Oral albendazole is the chemotherapy of
choice for both disease types, sometimes combined with
surgery or percutaneous drainage of the cysts. Albendazole
is poorly absorbed from the gastrointestinal tract and most
PK studies have focused on improving the bioavailability
of the compound [76–78].
The pharmacokinetics of albendazole and its main
metabolite, albendazole sulfoxide, have been studied in
patients with echinococcosis [76]. It was shown that
extrahepatic cholestasis, a common symptom of
echinococcosis, delayed the absorption and decreased the
elimination rate of albendazole. Another study looked at
bioequivalence between a novel emulsified formulation of
albendazole compared with a standard oral tablet formu-
lation [77]. To improve the low bioavailability of alben-
dazole, co-administration with cimetidine was studied [78].
The high inter-individual variability in drug exposure and
the various possible contradictory effects of cimetidine on
both absorption (increased) by decreasing the gastroin-
testinal pH and metabolism by cytochrome P450 enzyme
inhibition for both albendazole and its sulfoxide metabolite
complicated the descriptive interpretation of the results
from this study [78].
3.2.11 Food-Borne Trematodiases
Food-borne trematodiases are zoonotic infections caused
by parasitic flatworms, so-called ‘liver flukes’, which can
result in clonorchiasis, opisthorchiasis, fascioliasis, and
paragonimiasis. Transmission cycles differ widely, but
generally involve ingestion of food contaminated with the
parasite larvae. The worms are mainly located in the liver
and gall bladder or in the lung (paragonimiasis). Different
anti-helminthic compounds are used, depending on the
infecting worm (Table 3), but praziquantel and triclaben-
dazole are two of the main drugs in use for this group of
diseases. Pharmacokinetic studies were found for both
these drugs [79–82], although no studies were found in the
context of paragonimiasis (lung fluke). Given the liver
damage caused by the flukes, many PK studies focused on
a disease effect on cytochrome P450 enzyme-mediated
metabolism of the compounds, which appeared most
prominent for the cytochrome P450 3A4 substrate prazi-
quantel [79].
The bioavailability of triclabendazole, the drug of choice
for fascioliasis, and total exposure to activemetabolites were
shown to be greatly increased by concomitant food intake
[81]. Descriptive PK parameters were not different between
fascioliasis patients and healthy subjects, indicating the
absence of a disease effect on triclabendazole metabolism
despite obvious liver damage [82].
Praziquantel, the anti-helminth drug of choice for both
opisthorchiasis and clonorchiasis, appeared to have a
reduced clearance rate in advanced opisthorchiasis infection,
compared with early-stage disease and post-recovery, pre-
sumably owing to liver impairment [79]. In clonorchiasis
patients, a sustained-release formulation was tested to allow
for a single-dose treatment with praziquantel. Despite a
similar area under the concentration-time curve, the sus-
tained-release formulation with lower maximal concentra-
tion and peak time showed unsatisfactory efficacy compared
with single-dose normal-release praziquantel [80].
3.2.12 Lymphatic Filariasis
Lymphatic filariasis, also known as elephantiasis, is a dis-
figuring disease caused by filarial nematodes (roundworms)
and is a major cause of disability and social stigma in
endemic areas. The filarial worms are transmitted by mos-
quitoes and cause an infection of the lymphatic system and
skin, leading to massive edema formation in, for example,
extremities and genitalia. Current treatment is generally
through mass drug administration with the aim to stop
transmission of the disease by killing the microfilarial stage
of the parasite, using albendazole plus either ivermectin in
regions with onchocerciasis (i.e., African countries) or
albendazole plus diethylcarbamazine in all other regions.
Pharmacokinetic studies in the context of lymphatic filariasis
were found for both these combinations [83–85]. Doxycy-
cline has been proposed as a treatment to kill also adult
worms, but no PK studies could be identified for this drug in
this context.
Co-administration of diethylcarbamazine and albenda-
zole was investigated in healthy volunteers from areas
where lymphatic filariasis is endemic [83]. Whereas large
inter-individual variability in exposure of all drugs was
observed, no significant interaction was detected. To assess
the safety of albendazole mass drug administration during
breast feeding, the pharmacokinetics of albendazole and
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metabolites was studied in the breast milk of treated
women. Albendazole and albendazole sulfoxide achieved
low penetration into breast milk and was not considered to
be harmful for breastfed infants [85].
3.2.13 Onchocerciasis
Onchocerciasis, also known as river blindness, is caused by
the filarial nematode Onchocerca volvulus, which is
transmitted through the bites of blackfly that breed near
rivers. It results in various clinical manifestations, such as
pruritus, subcutaneous nodules, onchocercal skin disease,
and blindness. The therapeutic targets are the young
microfilariae located, for example, in the skin, as well as
the adult worms (macrofilariae) located generally in the
subcutaneous nodules. The clinical approach to treatment is
mainly focused on interrupting transmission through mass
drug administration programs with ivermectin (focused on
killing the microfilariae) at 6- to 12-monthly intervals,
sometimes in combination with albendazole owing to an
overlap with lymphatic filariasis co-infection. For indi-
vidual treatment, doxycycline is used in combination with
ivermectin. Various studies have investigated the pharma-
cokinetics of albendazole and ivermectin in onchocerciasis
patients, focusing on dose-finding, food-effect, compliance,
disease-effect, tissue distribution, and drug–drug interac-
tions [86–90]. No PK studies were found for doxycycline.
Other less established treatments include: suramin (too
toxic and costly [91]), moxidectin (under development
[92]), and amocarzine (insufficient efficacy [93, 94]).
Combining albendazole and ivermectin appeared to be
safe and not to result in any PK interactions; albendazole co-
administration offered no advantage over ivermectin alone
in terms of efficacy against onchocerciasis [86, 87]. A fatty
meal increased the bioavailability of albendazole fourfold
and concomitant food intake should thus be recommended
[86]. However, ivermectin pharmacokinetics was shown to
be not affected by either food or alcohol intake [90].
Ivermectin PK parameters were similar between healthy
volunteers and onchocerciasis patients and the drug was
shown to penetrate in fat, skin, infected nodules, and even
isolated parasites from these patients [89]. Compliance to
non-observed ivermectin therapy in mass drug adminis-
tration programs could be assessed through plasma con-
centration monitoring [88].
Pharmacokinetics of moxidectin, a veterinary anti-para-
sitic, was studied in healthy lactating women, including
excretion into breast milk [92]. Moxidectin exposure in
infants via breast milk was estimated to be 8.37 % of the
maternal dose, but PK information from young children is
necessary to fully understand the implications of this indirect
exposure.
The bioavailability of amocarzine, an experimental drug
for onchocerciasis, appeared to be poor in fasting condi-
tions. Additionally, the dosing interval was suggested to be
shortened to twice-daily administration to increase expo-
sure [93]. A subsequent study showed improved bioavail-
ability of amocarzine and exposure to its N-oxide
metabolite with food intake [94].
3.2.14 Schistosomiasis
Schistosomiasis is caused by Schistosoma blood flukes,
whose life cycle is dependent on fresh water snails.
Humans are infected through skin contact with contami-
nated water. The localization of the infection can vary
depending on the infective Schistosoma species and can
develop in the intestines, liver, spleen, lungs, bladder, or
urinary tract. The acute phase is characterized by a tran-
sient hypersensitivity reaction associated with tissue
migration of the larvae. Chronic infection can result in
many different clinical manifestations such as hematuria
(urogenital) or blood in the stool (intestinal), depending on
the infected organs. Control of schistosomiasis is based on
large-scale treatment mainly using praziquantel, which was
the topic of most PK studies in schistosomiasis [16, 95–97].
The hepatic and renal dysfunction associated with chronic
infection have been the focus of various praziquantel PK
studies, which is hepatically metabolized and renally
cleared. We also found descriptive PK studies for the
experimental drugs metrifonate [98] and oxamniquine [99].
In one schistosomiasis case with chronic kidney failure,
praziquantel plasma pharmacokinetics seemed not to be
affected. This could indicate that advanced schistosomiasis
can be treated with the regular praziquantel dose [95]. In
patients infected by Schistosoma mansoni with various
degrees of hepatic dysfunction, both the time to maximal
concentrations as well as the area under the concentration-
time curve increased proportionally with the degree of hep-
atic insufficiency [16]. Despite these PK differences, effi-
cacy appeared not to be affected and dose adjustments based
on hepatic function were not advised [16]. Pharmacokinetic
parameters of two formulations of praziquantel were com-
pared, to investigate a slower release formulation [96].
3.2.15 Soil-Transmitted Helminthiases
Soil-transmitted helminthiases are a diverse set of diseases
caused by intestinal worms and often affect the most poor
and rural communities. The main species that infect people
through contact with contaminated soil are the roundworm
(Ascaris), the whipworm (Trichuris), and the hookworms
(Necator and Ancylostoma). Treatment for these infections
is mainly through administration of antihelminths such as
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albendazole and mebendazole. Preventive treatment to
reduce transmission to endemic populations is also widely
used. No PK studies were identified.
3.2.16 Dengue, Chikungunya, and Zika
Dengue is the most prevalent arthropod-borne viral disease.
The Flavivirus infection can cause a wide range of clinical
manifestations of which severe hemorrhagic dengue is
potentially fatal. Chikungunya and zika, two other fla-
viviruses that are also transmitted by mosquitos, both cause
acute febrile polyarthralgia and arthritis. There are no
specific therapeutic treatments available for dengue,
chikungunya, or zika, although a few vaccines are currently
in development. However, no PK studies were identified for
these viral infections.
3.2.17 Rabies
Rabies is caused by a range of lyssaviruses and usually starts
with non-specific symptoms during the prodromal phase, but
once a patient is symptomatic the infection usually leads to
progressive encephalopathy and is virtually always fatal.
There are no established antiviral treatment regimens for
rabies, although various post-exposure prophylaxis sched-
ules based on vaccine therapy with or without rabies-specific
immunoglobulins are being used to prevent development of
symptomatic disease. Some PK studies have been performed
on the kinetics of administered anti-rabies antibodies [17, 18]
and administered human interferon to support an early
immune response [100].
Pharmacokinetics of human leukocyte interferon in CSF
was compared between systemic and local intraventricular
direct administration [100]. This study demonstrated that
interferon levels in the CSF could be maintained at
potentially therapeutically active levels, also by systemic
administration. Two other studies looked at immunoglob-
ulin antibody administrations to increase rabies antibody
titers. In one study, two sources of equine rabies
immunoglobulin were compared in terms of antigen-bind-
ing fragments, which showed similar time profiles, but no
bioequivalence [17]. A phase I study with a recombinant
human IgG1 anti-rabies monoclonal antibody determined
the required dose to use in future post-exposure prophy-
laxis studies based on antibody pharmacokinetics [18].
4 Discussion
This is the first comprehensive and systematic review of
clinical PK studies undertaken in the field of NTDs. Our
study highlights the paucity of PK data available for the
treatments used against NTDs and the lack of application
of modeling and simulation techniques in this particular
clinical area. For various NTDs (endemic treponematoses,
dracunculiasis, dengue/chikungunya, and soil-transmitted
helminthiasis), no PK studies could be identified at all,
while for others only very few studies (\5) were found
(Buruli ulcer, trachoma, echinococcosis, lymphatic filaria-
sis, food-borne trematodiases, and rabies). For diseases
such as soil-transmitted helminthiases and rabies, this lack
of PK studies is in stark contrast to their massive global
burden of disease (2700 and 26,400 deaths per year and
5.19 and 1.46 million disability-adjusted life-years,
respectively). Whereas for some of these diseases dedi-
cated chemotherapeutic options have never been available
(e.g., dracunculiasis and dengue), for other NTDs, multiple
drugs have been in clinical use for decades as part of
established treatment guidelines, but information on PK
studies is lacking. Owing to the consistent lack of research
and development funding for treatment of NTDs, very little
innovation has been witnessed in the past century for the
management of NTDs. For example, suramin, pentamidine,
and melarsoprol, which were discovered in 1920, 1940, and
1949, respectively, are still being used for human African
trypanosomiasis and leishmaniasis management. For all of
these drugs, no or very little PK studies have been per-
formed since their introduction (we identified one, two, and
five studies, respectively), while their live-threatening
toxicities and the continuous threat of emerging drug
resistance requires continued optimization of these dose
regimens. The gap of knowledge on pharmacokinetics and
PK–PD relationships limiting treatment optimization and
adaptation has been highlighted before, e.g., for prazi-
quantel [101] and schistosomiasis [102], but has largely
been neglected for other NTDs previously.
4.1 Limitations
Because our systematic review focused on clinical PK
studies, the term ‘pharmacokinetics’ was the most central
search term in our analysis. However, this term itself was
only been introduced in the field of pharmacology in 1953
by Dost and has been popularized in the two decades
afterwards [103]. Given that several current drugs against
NTDs have been in use for a few decades already, it could
be that various older publications for these particular NTD
drugs were not identified because they potentially did not
make mention of the term ‘pharmacokinetics’. This might
also explain that our two oldest identified studies date from
1980 [24, 98], which might thus be a biased observation.
While drug development activities in the field of NTDs
have substantially increased during the past 15 years,
mainly through increased political awareness and novel
innovation mechanisms such as the product development
partnership Drugs for Neglected Diseases initiative (http://
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www.dndi.org), this appeared not to be reflected in the
number of PK studies conducted. There is no particular
increasing trend in the number of clinical PK reports for
NTDs since 2000 (Fig. 2). On the contrary, more than half
of all identified PK studies were published prior to 2000,
with a peak of publications in the mid-1990s (seven studies
in 1993). This might indicate that, despite innovative
breakthroughs and increased clinical trial activities in the
field of NTDs, PK studies are still being neglected; an
observation corroborated by a recent review that found
only 4/382 active clinical trials on NTDs directed at PK
studies [9]. Regarding the type of PK analysis, there was an
increasing trend of using a population approach to analyze
the PK data over the past decade (Fig. 2).
A limitation in our search strategy was the English
language restriction, potentially missing papers, e.g. in
French from African journals or Chinese from Asian
journals. Additionally, (national) journals from countries/
regions where NTDs are endemic are not particularly well
covered by PubMed/MEDLINE. Theoretically, this might
have precluded our access to some literature, but given the
topic of our literature analysis this potential bias is prob-
ably in reality very small or even non-existent and more
relevant for clinical publications than PK publications.
While the list of NTDs used can be variable, the word
‘neglected’ in that term generally refers to the lack of
interest from the pharmaceutical industry and the overall
lack of funding and innovation in terms of therapeutic
research and development for these diseases, but also to
neglect by health ministries in countries where infected
people live, by the World Bank, or relative to human
immunodeficiency virus/acquired immune deficiency syn-
drome, tuberculosis, and malaria. Typically NTDs are
infectious diseases closely interrelated to poverty and
socioecological systems promoting close contact between
affected populations, vectors, and animal reservoirs.
Malaria, tuberculosis, and human immunodeficiency virus/
acquired immune deficiency syndrome are not considered
as NTDs. The list of NTDs has since the turn of the century
often been expanded to more than 30 diseases and disease
complexes [104]. We adhered to the list of NTDs put
forward by the WHO [1], which contains 17 items of which
various are disease ‘complexes’, such as ‘soil-transmitted
helminthiases’, comprising multiple clinical infectious
disorders.
4.2 Challenges in Clinical Pharmacokinetic Studies
in Patients with Neglected Tropical Diseases
In the rural settings in which NTD clinical trials take place,
collecting samples, maintaining cold chains, and generally
performing large clinical trials are logistically challenging.
Obtaining useful blood samples from patients can be
practically difficult owing to a lack of laboratory infras-
tructure and restrictive clinical characteristics such as
anemia. NTDs typically affect the poorest of the poor and
disadvantaged populations, inherently constituting ethical
difficulties, while language barriers and illiteracy make it
difficult to acquire informed consent from patients. Addi-
tionally, following up patients after their treatment, e.g., to
sample the elimination phase of a drug or identify long-
term outcome, is often practically impossible, e.g., in
nomadic populations. Moreover, there is limited research
and development funding available for the clinical devel-
opment of drugs for NTDs [9]. For all these reasons,
clinical trials on NTDs therefore typically result in small
and heterogeneous datasets. This is illustrated by our sys-
tematic review, as 94 % of the identified studies included
small patient numbers (n\ 50).
Patients in PK studies on NTDs are highly heteroge-
neous owing to variability in clinical characteristics such as
degree of liver impairment, malnourishment, or concomi-
tant underlying infections, which subsequently can lead to
large inter-individual variability in PK parameters. Many
studies in this review, e.g. almost all studies on cysticer-
cosis and taeniasis [69, 70, 72–75], reported large inter-
individual variabilities in PK profiles and parameters. That
large unexplained inter-individual variability can limit
conclusions of trials is also exemplified in our review. For
instance, in one study on Buruli ulcer, no significant dif-
ferences in PK parameters could be found between two
treatment groups because of the small population size and
high degree of inter-patient variability [55]. In another
study on albendazole in echinococcosis, a dose-dependent
increase of the active metabolite’s maximum plasma con-
centration could not be identified because of high intra- and
inter-individual variability in bioavailability [78]. Further-
more, in the PK studies, some attention has been paid to
drug–drug and food interactions (28 % of studies), but only
a few studies (11 %) made suggestions for optimizing
dosing. Furthermore, little attention has been paid to
exposure-response relationships (6 % of studies), which is
of high importance to make proper decisions regarding
dosing schemes.
4.3 Advantages of Pharmacometric Techniques
To optimize treatment regimens and to design efficient and
cost-effective clinical trials, the use of population-based
analyses can provide substantial advantages. The US Food
and Drug Administration and the European Medicines
Agency recommend the use of pharmacometrics in data
analysis and clinical trial designs, especially in pediatrics
or small patient groups [10–12]. Modeling and simulation
techniques are pivotal in designing and simulating dosing
regimens and trials and are a useful tool to extrapolate
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proposed regimens, e.g., from healthy to diseased popula-
tions. Particularly for pediatrics, the application of quan-
titative pharmacometric methods has been considered
essential to increase the success rates of clinical trials
[105]. Not only in a priori pediatric trial design, but par-
ticularly also in the a posteriori analysis of collected PK
(and PD) data, pharmacometric methods are needed to deal
with the typical pediatric challenges of small study popu-
lations and a low number of measurements [106]. For many
NTDs, e.g., human African trypanosomiasis, leishmaniasis,
soil-transmitted helminthiases, schistosomiasis, and den-
gue, more than 50 % of the burden of disease is occurring
in children [4].
The use of population-based approaches can aid in
understanding and explaining the heterogeneity in phar-
macokinetics and dealing with sparse sampling and smaller
sample sizes, which are all so typical for studies in NTDs
(see above). Physiological covariates could be identified to
understand factors that contribute to variability among
patients, even with a smaller sample size, unstructured
sampling time points, and sparse data per individual [107].
More information could be gained from studies with high
intra- and inter-individual variability when part of the
variability can be explained. Therefore, more emphasis on
identification of appropriate covariate and error models
could be particularly helpful, which requires the applica-
tion of pharmacometrics [108].
An additional complication with infectious diseases is
the need for combination therapy because of the fear of
emerging (or already existing) drug resistance of the cau-
sative pathogen, and also because of the presence of co-
infections. Identifying and understanding drug–drug inter-
actions is therefore important for NTDs, that often appear
in conjunction with malaria, human immunodeficiency
virus, or tuberculosis, and also here the use of pharmaco-
metrics has been recommended [108–110].
4.4 Extrapolations and Simulation-Based Studies
Only 11 % of the PK studies in our review included
pediatric populations, which is in dire contrast to the actual
burden of disease of most NTDs, as mentioned above.
Again, population PK studies offer many advantages in this
context. Pharmacokinetic models derived from the adult
population can be extrapolated to pediatric populations
based on appropriately identified physiological covariate
models [111]. Nevertheless, no studies were identified in
this review that actually employed such extrapolation.
Similar applications could be useful to extrapolate between
ethnic groups or between patients from different geo-
graphical regions, all of which are relevant owing to the
wide geographical distribution of many NTDs (Table 1).
Models could also be used to bridge PK results between
different diseases, as some NTD drugs are (primarily) used
for other diseases. For example, rifampicin is used for
tuberculosis, with various published population PK models
available, which could be extrapolated to assess PK–PD
relationships for its use in leprosy and Buruli ulcer patients.
Once PK and PK–PD models are developed and expo-
sure-response relationships are established, optimal dosing
schemes can be designed to reach the desired drug effect in
all patients. This can be achieved in a cost-effective way by
PK or PK–PD simulations of various dose regimens, taking
into account the actual variability in patient characteristics
in the target population. In our review, we identified only
four studies that actually made recommendations for
alternative dose regimens. These four studies performed
population PK analyses and subsequent simulations with
the developed models to define optimal doses
[25, 26, 38, 42]. Other PK studies, mainly employing non-
compartmental or individual compartmental analyses (to-
gether 78 %), typically made simple non-specific sugges-
tions to lower or increase the dose, or conclude that more
research was needed to suggest alternative doses. Addi-
tionally, for at least four studies we identified, a re-analysis
performed using population PK methods provided more
details about the PK–PD relationship or optimal dose
regimens, compared with previous reports of the same PK
datasets using conventional analysis methods
[26, 36, 38, 42].
Simulation-based studies can also help to limit and
assess potential toxicity of dose regimens. For example,
one study investigated the pharmacokinetics of benznida-
zole in Chagas disease patients [26], and simulations
revealed that the studied dose might lead to overexposure
in most patients. In another study, simulations showed that
the maximum ivermectin exposure used in combination
with azithromycin was in accordance with the safe expo-
sure that was observed previously [68]. Furthermore, we
identified two studies that assessed the toxicity of a drug to
infants exposed by breast feeding [23, 41]. In the first
study, the drug exposure in breast milk was simulated by
only using data from literature, and consequently the
exposure of the drug to the infant was predicted. This gave
insight into the potential exposure and toxicity in infants
without exposing actual infants to the drug. Another
example was the use of population-based simulations and
data from animal reproductive studies to define human
contraceptive cover periods for the potentially teratogenic
drug miltefosine for leishmaniasis [41]. Often there is a
lack of women included in clinical trials, but still insight
can be gained in drug exposure to women by the use of
simulation and extrapolation techniques. All these exam-
ples highlight the opportunities of applying pharmaco-
metric methods over more conventional analysis methods
in assessing therapeutics for NTDs.
L. Verrest, T. P. C. Dorlo
5 Conclusion
This review provides an overview of the current status and
gaps in PK research for NTDs, as well as the lack of
population-based modeling in the performed clinical trials.
Simulation and extrapolation tools have been minimally
applied. For many NTDs, no registered therapy is avail-
able, and more clinical PK trials are needed to establish
evidence-based treatments and define PK–PD relationships.
To make future clinical trials feasible and affordable,
population PK modeling should be used to optimally ana-
lyze the often sparse data available and simulation-based
studies should be used to inform trial design. This would
minimize risks and maximize success rates of clinical tri-
als, and optimally use the limited funding available in this
neglected clinical area.
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